National call for the generation of human recombinant antibodies

The Human Antibody Therapeutics (HAT) facility is part of the Drug Discovery and Development (DDD) Platform at SciLifeLab. In short, we help Swedish academic groups to translate basic science into disease intervention. More specifically, HAT engages in the development of therapeutic antibodies by making use of phage display technology and in house generated IP-free human recombinant antibody libraries.

In parallel to our normal activities, we are pleased to announce that a call to generate human recombinant antibody fragments for new targets is now open at the HAT facility.

Questions? Please contact Helena Persson Lotsholm, PhD, Head of Facility (helena.persson@scilifelab.se, 0704-171641)

The offer: We will isolate human antibody fragments (scFv or Fab) specific for antigens of therapeutic interest from our large combinatorial phage libraries. When successful we will deliver purified antibody fragments and gene sequences encoding these proteins.

Deadline for proposal submission: November 1st, 2017.

How to apply: Applications must be submitted on the dedicated form (please contact helena.persson@scilifelab.se for this). The application is provided to a limited group at the SciLifeLab DDD platform under conditions of confidentiality, solely for the purpose of evaluating and running the proposed project. Proposals will be reviewed and selected competitively according to therapeutic concept and technical feasibility.

Who can apply: The call is open to groups from both academia and industry, although different cost models will be applied. An academic PI will pay only for the consumables associated with the project, whereas industry users will pay the full cost associated with the project. If antibody fragments cannot be delivered to a particular target, the PI, academic or from the industry, will only be charged 25% of the estimated cost.

Technical aspects: If accepted, the principal investigator (PI) should be ready to provide at least 400 μg of purified soluble antigen, of which at least 300 μg should be biotinylated and 100 μg non-biotinylated, before November 1st, 2017. If the antigen does not meet our internal quality control, HAT reserves the right to terminate the project at which no charge should apply. After antigen delivery and passed quality control, we estimate about 4-6 months for antibody selection and screening of monoclonal soluble antibody fragments (until April-June, 2018). The selected antibody fragments will be included in a range of assays for studying antigen-binding interaction such as ELISA, HTRF and surface plasmon resonance as appropriate and feasible. At the end of the project, the Human Antibody Therapeutic facility will provide the PI with E.coli-produced and purified proteins of the selected and characterized antibody fragments, including the corresponding gene sequences, as well as all the results associated with the project.

Agreement: This work will be performed as a scientific collaboration. If results based on the use of the selected antibody fragments is published, accepted practice shall apply, whereby the persons who have actively contributed to the scientific discoveries shall be co-authors of the publication. The PI undertakes to acknowledge the SciLifeLab DDD platform in all publications concerning results generated within the project, also when DDD personnel are not listed as authors. DDD also reserves the right of using obtained results for a potential publication describing antibody library design and performance. However, any information that potentially might harm any future IP, such as sequence of obtained antibodies and target identity, will not be revealed in such publication. Intellectual property resulting from the project results may have both PI and DDD inventors in accordance with patent law. However, DDD personnel will not make ownership claims to intellectual property related to the project.